Inhibikase Therapeutics, Inc. (IKT) In The News https://www.inhibikase.com/news/in-the-news/rss en-us https://d1io3yog0oux5.cloudfront.net/_36dbb71928886c79e446b0ffcae1c0b0/inhibikase/files/theme/images/logo-sm.png Inhibikase Therapeutics, Inc. Logo https://www.inhibikase.com Equisolve Investor Relations Suite <![CDATA[Nulla iaculis, massa sit amet tempor pellentesque, sem ligula euismod metus, eget blandit tortor arcu eu nisl]]> https://www.inhibikase.com/news/in-the-news/detail/7600/nulla-iaculis-massa-sit-amet-tempor-pellentesque-sem Thu, 03 Jul 14 00:00:00 -0400 https://www.inhibikase.com/news/in-the-news/detail/7600/nulla-iaculis-massa-sit-amet-tempor-pellentesque-sem <![CDATA[Aliquam convallis turpis urna, ut dapibus arcu faucibus interdum]]> https://www.inhibikase.com/news/in-the-news/detail/7599/aliquam-convallis-turpis-urna-ut-dapibus-arcu-faucibus Wed, 02 Jul 14 00:00:00 -0400 https://www.inhibikase.com/news/in-the-news/detail/7599/aliquam-convallis-turpis-urna-ut-dapibus-arcu-faucibus <![CDATA[Lorem ipsum dolor sit amet, consectetur adipiscing elit]]> https://www.inhibikase.com/news/in-the-news/detail/7598/lorem-ipsum-dolor-sit-amet-consectetur-adipiscing-elit Tue, 01 Jul 14 00:00:00 -0400 https://www.inhibikase.com/news/in-the-news/detail/7598/lorem-ipsum-dolor-sit-amet-consectetur-adipiscing-elit